Cat. No.: HY-N0242

Fraxinellone

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.

For research use only. We do not sell to patients.

Purity: 99.91%
CAS No.: 28808-62-0
Formula: C₁₄H₁₆O₃
Molecular Weight:232.28

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fraxinellone Chemical Structure

CAS No.: 28808-62-0

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All HIF/HIF Prolyl-Hydroxylase Isoforms :

All STAT Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CAL-27	IC₅₀	22.4 μg/mL Compound: Frax	Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 34463097]
SCC-9	IC₅₀	43.4 μg/mL Compound: Frax	Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 34463097]

In Vitro

Fraxinellone (0-100 μM；12 hours) decreases the percent of PD-L1 positive cells from 20.4% to 11.4% in A549 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

A549 cells
Concentration:

0 μM, 10 μM, 30 μM, 100 μM
Incubation Time:

12 hours
Result:

Inhibited the percent of PD-L1 positive cells.

In Vivo

Fraxinellone (oral gavage; 30 and 100?mg/kg; every three days; 30 days) significantly suppresses tumor growth, reduces HIF-1α, pTyr705 STAT3, PD-L1 and VEGF staining compared with the control group in female athymic BALB/c nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice^[1]
Dosage:

30 and 100 mg/kg
Administration:

Oral gavage; 30 and 100 mg/kg; every three days; 30 days
Result:

Significantly suppressed tumor growth.

Chemical Information

CAS No. 28808-62-0
Appearance Solid
Molecular Weight 232.28
Formula C₁₄H₁₆O₃
Color White to off-white
SMILES

O=C1O[C@@H](C2=COC=C2)[C@]3(C)CCCC(C)=C31
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All RT-PCRWBCell Proliferation/Viability AssayIHCIF

Sort by:

Journal Impact Factor

Biomed Pharmacother

Fraxinellone protects against cardiac injury and decreases ventricular fibrillation susceptibility during myocardial ischemia-reperfusion. [Abstract]

2024 Nov:180:117560. PMID: 39442236

Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]

mRNA content of IL6, TNFα and IL1β treated with Fraxinellone (FRA) (5 mg/kg, i.p.).

Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]

Western blot analysis of Bax and BCL2 treated with Fraxinellone (FRA) (5 mg/kg, i.p.)

Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]

Cell viability was measured by CCK8 treated with Fraxinellone (FRA) (20, 40, 80, 160 μM).

Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]

The typical representative of TH and GAP43 immunohistochemical staining in myocardial tissue treated with Fraxinellone (FRA) (5 mg/kg, i.p.).

Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]

The representative images of Cx43 immunofluorescence staining in myocardial tissue treated with Fraxinellone (FRA) (5 mg/kg, i.p.).
Biomed Pharmacother

Fraxinellone inhibits progression of glioblastoma via regulating the SIRT3 signaling pathway. [Abstract]

2022 Sep:153:113416. PMID: 36076484
Int Immunopharmacol

Fraxinellone alleviates colitis-related intestinal fibrosis by blocking the circuit between PD-1+ Th17 cells and fibroblasts. [Abstract]

2024 May 21:135:112298. PMID: 38776854
Int J Biochem Cell Biol

Inhibition of ERO1A by TCF21 curbs aerobic glycolysis and enhances immune recognition in lung adenocarcinoma. [Abstract]

2025 Oct:187:106831. PMID: 40659157

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (430.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3051 mL

21.5257 mL

43.0515 mL

5 mM

0.8610 mL

4.3051 mL

8.6103 mL

10 mM

0.4305 mL

2.1526 mL

4.3051 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xing Y, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Pharmacol Res. 2018 Sep;135:166-180. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3051 mL	21.5257 mL	43.0515 mL	107.6287 mL
	5 mM	0.8610 mL	4.3051 mL	8.6103 mL	21.5257 mL
	10 mM	0.4305 mL	2.1526 mL	4.3051 mL	10.7629 mL
	15 mM	0.2870 mL	1.4350 mL	2.8701 mL	7.1752 mL
	20 mM	0.2153 mL	1.0763 mL	2.1526 mL	5.3814 mL
	25 mM	0.1722 mL	0.8610 mL	1.7221 mL	4.3051 mL
	30 mM	0.1435 mL	0.7175 mL	1.4350 mL	3.5876 mL
	40 mM	0.1076 mL	0.5381 mL	1.0763 mL	2.6907 mL
	50 mM	0.0861 mL	0.4305 mL	0.8610 mL	2.1526 mL
	60 mM	0.0718 mL	0.3588 mL	0.7175 mL	1.7938 mL
	80 mM	0.0538 mL	0.2691 mL	0.5381 mL	1.3454 mL
	100 mM	0.0431 mL	0.2153 mL	0.4305 mL	1.0763 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Fraxinellone

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Fraxinellone

All HIF/HIF Prolyl-Hydroxylase Isoforms

All STAT Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Fraxinellone Related Classifications

Cat. No.: HY-N0242